gC1qR, also named P32/C1qBP/HABP1, a receptor for globular heads of C1q, has begun to garner significant interest in the immune-oncology field as a novel potential target (16, 17). This protein bound with high affinity to the globular heads of C1q under physiological ionic strength .

2023年1月26日 · In this review, we focus on the current understanding of gC1qR function in cancer immunology and highlight the vital roles in regulating the TME. We also examines the rationale behind targeting gC1qR and discusses the potential for translating into clinical practice.

2021年12月4日 · C1qbp（补体C1q结合蛋白，又称为p32或gC1qR）是一种已知的对线粒体氧化磷酸化很重要的多功能蛋白，能通过结合RNA的方式促进线粒体基因编码蛋白的翻译。

2019年10月1日 · These findings indicated that recombinant gC1qR, and by analogy, secreted gC1qR, is an effective inhibitor of HIV-1 infection, and prevents viral entry by blocking the interaction between CD4 and gp120 [78].

gC1qR，也称为 P32/C1qBP/HABP1，是一种多功能蛋白，在多种癌症中过度表达并具有预后价值。 它调节致瘤性，通过几个下游信号通路，包括 Wnt/β-连环蛋白、PKC–NF-κB 和 Akt/PKB 通路，了解肿瘤细胞的进展和转移特性。

gC1qR被认为是重要的病原体识别受体[PRR]。 鉴于其在越来越多的疾病设置中扮演着众多角色，gC1qR现在已成为开发基于单克隆抗体和/或基于小分子的疗法的潜在目标。

The gC1qR (i.e., gC1q receptor, gC1q binding protein, p32, p33) is a multifunctional cellular protein that interacts with components of the complement, kinin, and coagulation cascades and select microbial pathogens. Enhanced gC1qR expression has been reported in adenocarcinomas arising in a variety of organs.

To date, four types of putative C1q binding cell surface expressed proteins/receptors have been described. These include cC1q-R/CR, or calreticulin (CR), a 60 kDa protein, which is also known as collectin receptor; gC1q-R/p33, a 33 kDa homotrimeric protein; C1q-Rp (CD93), a 120 kDa, O-sialoglycoprotein; and CR1 (CD35), the receptor for C3b.

gC1qR是补体蛋白C1q的受体。 近年来的研究发现，该受体可选择性的调节细菌脂多糖（LPS）对炎性因子的诱导。 但是这种选择性调节的机制还没有被完全认识。

2020年7月14日 · In summary, gC1qR suppressed the MM-inhibiting role of C1q and regulated CKS1B mRNA in promoting tumor proliferation via IGF2BP3 in 1q21-amplified MM. Our findings provide novel evidence on how MM cells evade the immune system and promote survival as well as suggest possible novel targets for future therapies of MM.